[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastroesophageal-reflux-in-children\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastroesophageal-reflux-in-children":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100389996","study-on-the-efficacy-and-tolerance-of-a-new-anti-regurgitation-infant-formula-stellar-100389996",false,"NCT04358146","Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula (STELLAR)","Study on the Efficacy and Tolerance of a New Anti-regurgitation Infant Formula: a Double-blind, Randomized, Controlled, International, Multi-centric Clinical Trial","STELLAR","Inclusion Criteria:\n\n* ≥ 2 regurgitation episodes per day during the last 2 weeks and ≥ 4 regurgitation episodes per day in average during the last 2 days,\n* exclusive or predominant formula feeding\n* whose parents signed informed consent\n\nExclusion Criteria:\n\n* preterm infants or birthweight \\\u003C2500g\n* Post enteritis lactose intolerance\n* Suspected or diagnosed cow's milk protein allergy requiring an eviction diet\n* Use of medications that may interfere with regurgitation or gastrointestinal transit (such as alginates, laxatives, antibiotics...). All these medications have to be stopped at least 7 days before inclusion visit (V1)\n* Infants presenting with any situation which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the subject","ALL","2 Weeks","4 Months",{"count":21,"type":22},346,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of the study is to assess the effectiveness of this new formula on regurgitations and secondarily its effect on digestive tolerance through a randomized, controlled, double-blind trial against a comparator.",[28],"Gastroesophageal Reflux in Children",[30],"Reflux","RECRUITING","2026-04-30",{"date":34,"type":35},"2026-05-04","ACTUAL",{"date":37,"type":35},"2023-03-17",{"date":39,"type":22},"2026-12-03",{"name":41,"class":42},"United Pharmaceuticals","INDUSTRY",12]